Keystone Financial Planning Inc. Boosts Stake in GlaxoSmithKline PLC (GSK)

Keystone Financial Planning Inc. raised its position in GlaxoSmithKline PLC (NYSE:GSK) by 1.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 131,006 shares of the pharmaceutical company’s stock after buying an additional 1,514 shares during the period. GlaxoSmithKline PLC comprises about 3.4% of Keystone Financial Planning Inc.’s investment portfolio, making the stock its 11th largest position. Keystone Financial Planning Inc.’s holdings in GlaxoSmithKline PLC were worth $5,649,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. 10 15 Associates Inc. boosted its position in shares of GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares during the last quarter. Lincluden Management Ltd. boosted its position in shares of GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares during the last quarter. Anchor Capital Advisors LLC boosted its position in shares of GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares during the last quarter. BlueCrest Capital Management Ltd boosted its position in shares of GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock worth $2,157,000 after buying an additional 38,157 shares during the last quarter. Finally, Roundview Capital LLC boosted its position in shares of GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock worth $1,034,000 after buying an additional 15,000 shares during the last quarter. Institutional investors own 8.96% of the company’s stock.

GlaxoSmithKline PLC (GSK) opened at 38.79 on Friday. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.59. The firm has a market cap of $94.80 billion, a price-to-earnings ratio of 37.51 and a beta of 1.03. The company’s 50-day moving average is $41.84 and its 200 day moving average is $41.84.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. The business had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities research analysts predict that GlaxoSmithKline PLC will post $2.85 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be given a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a yield of 5.06%. The ex-dividend date is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.

WARNING: “Keystone Financial Planning Inc. Boosts Stake in GlaxoSmithKline PLC (GSK)” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/12/keystone-financial-planning-inc-boosts-stake-in-glaxosmithkline-plc-gsk.html.

GSK has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. TheStreet raised shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Finally, Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $46.00.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply